Sustained reduction in the carriage of Neisseria meningitidis as a result of a community meningococcal disease control programme

Epidemiology and Infection

Volumn 121, Issue 3, 1998, Pages 487-493

  Neal, K R ^a   Irwin, D J ^b,f   Davies, S ^c   Kaczmarski, E B ^d   Wale, M C J ^e  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b Rotherham Health Authority   (United Kingdom)

^c Public Health Laboratory   (United Kingdom)

^d Greater Manchester Health Protection Unit   (United Kingdom)

^e Communic Dis Survlnc Centre Trent ^*  (United Kingdom)

^f North Essex Health Authority   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; MENINGITIS VACCINE;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL; COMMUNITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HIGH SCHOOL; HUMAN; IMMUNIZATION; MAJOR CLINICAL STUDY; MALE; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PUPIL; SCHOOL CHILD; SOCIAL STATUS; THROAT CULTURE;

ADOLESCENT; AGE FACTORS; ANTI-BACTERIAL AGENTS; CARRIER STATE; CHILD; HUMANS; MENINGOCOCCAL INFECTIONS; NEISSERIA MENINGITIDIS; PHARYNX; VACCINATION;

EID: 0032410226     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0950268898001502     Document Type: Article

References (28)

1. Jackson LA, Schuchat A, Reeves MW, Wenger JD. Serogroup C meningococcal outbreaks in the United States. An emerging threat. JAMA 1995; 273: 383-9.
2. Irwin DJ, Miller JM, Milner PC, et al. Community immunisation programme in response to an outbreak of invasive Neisseria meningitidis serogroup C infection in the Trent region of England 1995-1996. J Publ Hlth Med 1997; 19: 162-70.
3. Invasive meningococcal infections, England and Wales: laboratory reports, weeks 51/95-03/96. CDR 1996; 6 (4): 30-1.
4. Irwin DJ, Kaczmarski EB, Miller J. A case of invasive serogroup C meningococcal disease after a community vaccination programme in Rotherham, S. Yorks. J Publ Hlth Med 1998; 20: 112-4.
5. Stuart JM, Monk PN, Lewis DA, Constantine C, Kaczmarski EB, Cartwright KAV on behalf of the PHLS Meningococcus Working Group and Public Health Medicine Environmental Group. Management of clusters of meningococcal disease. CDR Rev 1997; 7 (1): R3-5.
6. Control and prevention of serogroup C meningococcal disease: Evaluation and management of suspected outbreaks. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997; 46(RR-5): 13-21.
7. Gold R, Golschneider I, Lepow ML, Draper TF, Randolph M. Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J Infect Dis 1978; 137: 112-21.
8. Rosentein N, Levine O, Taylor JP, et al. Efficacy of meningococcal vaccine and barriers to vaccination in a U.S. community. JAMA 1998; 279: 435-9.
9. Jarman B. Identification of underprivileged area. BMJ 1983; 286: 1705-8.
10. Eldridge J, Sutcliffe EM, Abbott JD. Serological grouping of meningococci and detection of antigen in cerebrospinal fluid by co-agglutination. Med Lab Sci 1978; 35: 63-6.
11. Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. BMJ 1995; 310: 170.
12. Le Saux N, Ashton F, Rahman M, et al. Carriage of Neisseria species in communities with different rates of meningococcal disease. Can J Infect Dis 1992; 3: 60-4.
13. Rønne T, Berthelson L, Buhl LH, Lind I. Comparative studies on pharyngeal carriage of Neisseria meningitidis during a localised outbreak of serogroup C meningococcal disease. Scand J Infect Dis 1993; 25: 331-9.
14. Jacobsen JA, Chester TJ, Fraser DW. An epidemic of disease due to serogroup B Neisseria meningitidis in Alabama: Report of an investigation and community-wide prophylaxis with a sulfonamide. J Infect Dis 1977; 136: 104-8.
15. Cartwright KAV, Stuart JM, Jones DM, Noah ND. The Stonehouse survey: nasopharyngeal carriage of meningococci and Neisseria lactamica. Epidemiol Infect 1987; 99: 591-601.
16. Davies AL, O'Flanagan D, Salmon RL, Coleman TJ. Risk factors for Neisseria meningitidis in a school during a community outbreak of meningococcal disease. Epidemiol Infect 1996; 117: 259-66.
17. Hassan-King MKA, Wall RA, Greenwood BM. Meningococcal carriage, meningococcal disease and vaccination. J Infect 1988; 16: 55-9.
18. Mackenzie IF, Nelder R, Maconachie M, Radford G. 'My ward is more deprived than yours'. J Pub HIth Med 1998; 20: 186-90.
19. Stuart JM, Cartwright KAV, Dawson JA, Rickard J, Noah ND. Risk factors for meningococcal disease: a case control study in south west England. Commun Med 1988; 10: 139-46.
20. Stanwell-Smith RE, Stuart JM, Hughes AO, Robinson P, Griffin MB, Cartwright K. Smoking, the environment and meningococcal disease: a case control study. Epidemiol Infect 1994; 112: 315-28.
21. Cartwright K. Meningococcal carriage and disease. In Cartwright K, ed. Meningococcal disease. Chichester: John Wiley and Sons, 1995, 115-46.
22. Kremastinou J, Blackwell C, Tzanakaki G, Kallergi C, Elton R, Weir D. Parental smoking and carriage of Neisseria meningitidis among Greek schoolchildren. Scand J Infect Dis 1994; 26: 719-23.
23. Olcén P, Kjellander J, Danielsson D, Lindquist BL. Epidemiology of Neisseria meningitidis: prevalence and symptoms from the upper respiratory tract in family members to patients with meningococcal disease. Scand J Infect Dis 1981; 13: 105-9.
24. Stuart JM, Cartwright KAV, Robinson PM, Noah ND. Effect of smoking on meningococcal carriage. Lancet 1989; ii: 723-5.
25. 90 and eradication of nasopharyngeal carriage of bacteria. J Infect Dis 1990; 162: 1124-7.
26. Nicolle IE, Postl B, Kotelwetz, et al. Chemoprophylaxis for Neisseria meningitidis in an isolated arctic community. J Infect Dis 1981; 145: 103-9.
27. Sivonen A, Renkonen O-V, Weckström, Koskenvuo K, Raunio V, Mäkelä PH. The effect of chemoprophylactic use of rifampicin and minocycline on rates of carriage of Neisseria meningitidis in army recruits in Finland. J Infect Dis 1978; 137: 238-44.
28. Pearce MC, Sheridan JW, Jones DM, et al. Control of group C meningococcal disease in Australian Aboriginal children by mass rifampicin chemoprophylaxis and vaccination. Lancet 1995; 346: 20-3.